Abeona Therapeutics, Inc. (NASDAQ:ABEO)

About the company

Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.

Sector

Health Technology

Industry

Pharmaceuticals: Generic

Employees

88

$3.00M

Total Revenue

88

Employees

$210.80M

Market Capitalization

-2.07

Price/Earning ratio

Stock price

Gross Margin (in %)

Total gross margin

$3M

Operating Margin (in %)

Total operating margin

$-10M

Net Margin (in %)

Total net margin

$2M

Dividend Yield (in %)

Dividend per share

$0

Industry peers

Name Ticker Market capitalization (in USD Million) Revenues (in USD Million) Price/Book Price/Earning Net margin (in %)
Zoetis, Inc. ZTS 66589.64 6339.00 23.87 41.45 25.41
Mylan NV MYL 8551.18 11624.00 0.76 137.83 0.54
BridgeBio Pharma, Inc. BBIO 3807.87 41.00 10.02 -13.11 -718.08
Taro Pharmaceutical Industries Ltd. TARO 2500.78 645.00 1.20 10.36 37.88
TherapeuticsMD, Inc. TXMD 388.62 58.00 -9.00 -1.99 -333.88
Abeona Therapeutics, Inc. ABEO 210.80 3.00 2.15 -2.07 75.95
LifeVantage Corp. LFVN 195.45 230.00 6.55 16.49 5.06
Kindred Biosciences, Inc. KIN 150.93 4.00 2.51 -2.21 None
Cocrystal Pharma, Inc. COCP 53.55 2.00 1.96 -0.92 -733.84
China Pharma Holdings, Inc. CPHI 25.04 10.00 2.99 -1.16 -214.63
Jaguar Health, Inc. JAGX 5.05 5.00 3.74 0.08 -887.14

Latest insider transactions

Date Role Name Transaction Quantity Quantity Owned After

BRIEF-Abeona Therapeutics Reinitiates Enrollment In EB-101 Pivotal Phase 3 Viital™ Study In RDEB After Covid-19 Related Pause

14h ago, source: Reuters

ABEONA THERAPEUTICS REINITIATES ENROLLMENT IN EB-101 PIVOTAL PHASE 3 VIITAL™ STUDY IN RDEB AFTER COVID-19 RELATED PAUSE AND ANNOUNCES PROGRESS IN PATIENT ENROLLMENT IN MPS III STUDIES Source text for ...

Abeona Therapeutics Inc.: Abeona Announces Pricing of Public Offering of Common Stock and Pre‑Funded Warrants

3d ago, source: Bloomberg

Before it's here, it's on the Bloomberg Terminal.

Abeona resume enrollment in late-stage study of gene therapy in rare skin blistering disorder

13h ago, source: Seeking Alpha

Emerging from the temporary pause due to COVID-19 disruptions, (NASDAQ:ABEO) has restarted enrollment in its pivotal Phase 3 clinical trial, VIITAL, evaluating gene therapy EB-101 in patients with ...

ABEO Abeona Therapeutics Inc. Common Stock

13d ago, source: Nasdaq

Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.

Hedge Funds Still Crazy About Abeona Therapeutics Inc (ABEO)?

15d ago, source: YAHOO!

Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive ...

Abeona Therapeutics Inc.

7d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...



Portfolio items

Follow companies to create your optimal portfolio.
or
Refresh this page to see your newly added stocks.